Kornimate/medical-research-clean huggingface dataset:
circulating tumor dna and follow-up of brca1 mutation carriers (circa 01)

Conditions: Women With BRCA1 Germline Deleterious Mutation

Summary: brca1 carriers who are at high risk of developing either a relapse and/or a new cancer growth will be included. these patients will be followed up during 30 months (2,5 years) with mutated tp53 mutation detection or during 42 months (3,5 years) with mutated tp53 mutation detection and circulating tumor cells detection (ctc) performed at each hospital visit (for technical reason only patients included at institut curie will be proposed to participate to the ctc substudy).


Eligibility criteria:
inclusion criteria: 1. patient with no evidence of any invasive tumor mass at inclusion (clinical and, if any, radiological exams) 2. carriers of known germline brca1 deleterious mutation (a personal history of cancer is not mandatory). 3. age ≥ 30 years for patient with personal previous history of cancer 4. age ≥ 40 years for patient without personal previous history of cancer 5. patient who a follow-up visit is scheduled in the including center at least once a year 6. patient having health care insurance 7. signed informed consent by patient exclusion criteria: 1. patient presenting with invasive tumor masses (e.g. stage iv cancer or localized cancer not yet surgically removed) 2. carriers of germline brca1 variant of unknown significance 3. carriers of germline brca2 deleterious mutation or variant 4. individuals with a low risk of brca1-related tumor growth, i.e. women who underwent prophylactic bilateral mastectomy and adnexectomy. 5. any medical or other condition that in the investigator's opinion rendered the patient unsuitable for this study 6. patient deprived from ability to decide on her own. 7. patient unable to have a regular follow up for geographical, social or psychological reasons.

Keywords: circulating tumor dna brca1 mutation circulating tumor cells
efficacy of the individual placement and support (ips) model

Conditions: Substance Use Disorders

Summary: hypothesis 1. consumers with disabilities and co-occurring sud receiving ips will be more likely to be competitively employed (defined as 1 or more days of work over the past 30 days) at 3, 6 and 12 months following the initiation of vocational treatment goals when compared to a group receiving standard services. hypothesis 2. consumers with disabilities and co-occurring sud receiving ips when compared to the comparison group will 1.) be more successful in achieving their employment goals as indicated by the ratio of hours worked to desired hours worked; 2.) become competitively employed sooner; 3.) earn higher wages, 4.) have greater job satisfaction, 5.) have greater economic satisfaction; 6.) have greater life satisfaction, 7.) have greater self-esteem, and 8.) have fewer days of using substances during follow-up points.

hypothesis 1. consumers with disabilities and co-occurring sud receiving ips will be more likely to be competitively employed (defined as 1 or more days of work over the past 30 days) at 3, 6 and 12 months following the initiation of vocational treatment goals when compared to a group receiving standard services. hypothesis 2. consumers with disabilities and co-occurring sud receiving ips when compared to the comparison group will 1.) be more successful in achieving their employment goals as indicated by the ratio of hours worked to desired hours worked; 2.) become competitively employed sooner; 3.) earn higher wages, 4.) have greater job satisfaction, 5.) have greater economic satisfaction; 6.) have greater life satisfaction, 7.) have greater self-esteem, and 8.) have fewer days of using substances during follow-up points.

Eligibility criteria:
inclusion criteria: * inclusion criteria includes consumers who are between the ages of 18-65, able to provide informed consent for participation, and are initiating an employment goal in their treatment plan. exclusion criteria: * exclusion criteria includes anyone who is currently employed and has been for the past 30 days, have an open case with the ohio rehabilitation services commission, or have an open case with another vocational rehabilitation provider.

Keywords: employment, disabilities
efficacy of pentoxifylline on chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: to study whether pentoxifylline has additive renoprotective effect in patients taking arb

in patients with ckd and serum creatinine 1.3\~6.0 md/gl, having taken losartan 100 mg/day for at least 3 months, with stable renal function, will be recruited to a randomized open-label trial. patients taking pentoxifylline or not will be compared for their spot urinary proteinuria, estimated glomerular filtration, spot urine tumor necrosis factor-α/creatinine ratio, spot urine monocyte-chemoattractant protein-1/creatinine, and aldosterone concentration between groups in a 2-year study. add-on pentoxifylline in control group in the same dose as in treat group will be performed to observe the renoprotective effect if any protective potential is demonstrated in the end of maintenance 12 months.

Eligibility criteria:
inclusion criteria: * chronic kidney disease with serum creatinine 1.3\~6.0 mg/dl exclusion criteria: * history of allergy to pentoxifylline * females are nursing or pregnant * obstructive uropathy * unable to stop chronic immunosuppressive therapy, nsaid * congestive heart failure (new york heart association functional class iii or iv) * unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, within the past 6 months prior to signing the informed consent form * cerebral hemorrhage within the past 6 months prior to signing the informed consent form * retinal hemorrhage within the past 6 months prior to signing the informed consent form * known or suspected secondary hypertension (e.g., primary aldosteronism, renovascular hypertension, pheochromocytoma) * severe uncontrolled hypertension with sbp \> 220 mmhg and/or dbp \> 115 mmhg * hepatic dysfunction as defined by the following laboratory parameters: alt or ast \> 2 times the upper limit of the normal range * biliary obstructive disorders (e.g. cholestasis) * active malignancy

Keywords: ckd, pentoxifylline
nutritional risk screening nutritional support gastrointestinal cancer

Conditions: Gastrointestinal Cancer

Summary: the goal of this clinical trial was to compare the effects of different nutritional support methods based on nutritional risk screening on postoperative nutritional status in patients with gastrointestinal tumors.the main question it aims to answer is that different types of nutrition can improve the nutritional status of patients with different nutritional status;long-term dietary interventions for patients with poor nutrition can make cancer patients better able to tolerate surgery and chemotherapy and improve their quality of life.the intervention group received nutrition + exercise + psychological intervention upon admission, routine parenteral and enteral nutrition support after operation, and continued nutrition + exercise + psychological intervention after discharge.the control group received routine parenteral nutrition support in the department after surgery, and the patients and their families were given diet education during hospitalization.

purpose: the investigators conducted nutritional risk screening for patients with gastrointestinal tumors, gave different nutritional support methods to patients with different nutritional status, and analyzed the changes of various nutritional indexes of patients before and after nutritional intervention. methods: a total of 302 patients with gastrointestinal tumors admitted to the first hospital of shanxi medical university from july 2021 to june 2023 were selected.all patients underwent nutritional risk screening after admission and were divided into intervention group (nrs2002≥3 and pg=sga≥4, n=204) and control group (nrs2002 \< 3 or pg=sga \< 4 , n=98) according to the screening results.different nutritional interventions were given to analyze the changes of nrs-2002 and pg-sga scores between the two groups before and after propensity score matching, and compare the changes of dietary energy, dietary protein, total energy, total protein, body mass index (bmi), fat-free weight, walking time, grip strength and other nutritional indicators (hemoglobin, albumin, prealbumin) between the two groups.the effects of disease type and age on the results were compared by stratified analysis.

Eligibility criteria:
* inclusion criteria: 1. age ≥ 18 years； 2. the first pathological diagnosis was gastric or colorectal cancer and radical resection of malignant tumor was performed； 3. conscious, able to read, write and understand the study； 4. sign informed consent and participate in this study voluntarily. * exclusion criteria: 1. patients with malignant tumors at other sites； 2. patients undergoing neoadjuvant chemotherapy before surgery； 3. anastomotic fistula, anastomotic obstruction, gastroparesis and other serious complications occurred after operation； 4. there are mental disorders, psychological disorders； 5. patients who did not cooperate to complete the full intervention or follow-up records were missing； 6. patients with missing baseline data and nutritional risk screening results.
visual outcomes of topography guided photorefractive keratectomy (prk) for treatment of patients with irregular cornea

Conditions: Irregular Astigmatism

Summary: irregular astigmatism is one of the most serious and frequent complications of corneal refractive surgery and one of the worst sequelae of other forms of corneal surgery . it is also considered as one of common, serious complications of corneal injuries . spectacle correction is usually not useful in the correction of corneal irregular astigmatism. contact lenses represent a good alternative, but their adaptation and stability are limited by the irregular corneal surface and patient discomfort. in recent years, advancements in laser technology have offered better tools for dealing with irregular astigmatism with finding new surgical methods to improve corneal regularity for the correction of irregular astigmatism. topography-linked excimer laser is a potentially effective technique in the treatment of irregular astigmatism after keratoplasty . in fact, customized ablation was shown to be an effective means of treatment of irregular astigmatism due to different etiologies such as corneal injuries , scar , or postoperative. some of the theoretical advantages of topography-driven photorefractive keratectomy (prk) are a better astigmatic correction, the possibility of correcting irregular astigmatism, and a smaller ablation volume compared with standard treatments, resulting in better visual performance. aim of the work to evaluate the efficacy, safety, and predictability of topography-guided photorefractive keratectomy (prk) to improve refractive status of patient with irregular cornea.


Eligibility criteria:
inclusion criteria: * patients with irregular corneal astigmatism caused by: * trauma. * non - central corneal scars. * previous corneal surgery. * with no other abnormalities in the eye. * patient is willing to enter the study and sign a consent. exclusion criteria: * patients with central corneal scars. * patients with central haze interfering with visual acuity. * patients with ectasia at corneal graft margins. * patients with irregular astigmatism caused by corneal ectasia or keratoconus. * patients had refractive surgery with ablations leaving a residual corneal thickness less than 250 μm.
comparison of point of care to lab inr in dialysis patients on warfarin

Conditions: Anticoagulation in Dialysis Patients

Summary: to determine whether point of care (poc) international normalized ratio (inr) test results correlate with plasma inr measures in hemodialysis patients.

37 chronic hemodialysis patients being anticoagulated with warfarin require inr monitoring routinely.

Eligibility criteria:
inclusion criteria: * chronic dialysis patients on chronic warfarin anticoagulation. exclusion criteria: * on warfarin for less than 1 month.

Keywords: anticoagulation in dialysis patients chronic anticoagulation warfarin hemodialysis inr point of care
analysis of the efficacy and stability of a wearable ecg monitor

Conditions: Arrhythmias, Cardiac; Bradycardia; Tachycardia; Atrial Fibrillation; Atrial Flutter; Ventricular Premature Complexes

Summary: this study aims to analyze the efficacy and safety of wearable electrocardiogram (ecg) monitoring by simultaneously attaching a single-channel patch-type wearable ecg monitoring device (hicardi+ by mezoo co., ltd.) and a telemetry device (intellivue mx40 by philips) used in actual wards to patients prescribed with ecg monitoring

this study aims to analyze the efficacy and safety of wearable electrocardiogram (ecg) monitoring by simultaneously attaching a single-channel patch-type wearable ecg monitoring device (hicardi+ by mezoo co., ltd.) and a telemetry device (intellivue mx40 by philips) used in actual wards to patients prescribed with ecg monitoring. after the data collection is completed, a satisfaction survey will be conducted with the medical staff. the data obtained simultaneously from hicardi+ and mx40 will be analyzed, and the satisfaction survey responses from the medical staff will be reviewed to confirm the clinical convenience of the patch-type ecg monitoring device.

Eligibility criteria:
inclusion criteria: 1. adults aged 19 years or older 2. patients admitted to chonnam national university hospital who require ecg monitoring 3. individuals who have expressed their intention to participate in this study or have obtained written consent from a proxy exclusion criteria: 1. individuals who are unable to provide consent themselves or through a legally designated representative 2. individuals deemed unsuitable for participation in the clinical trial based on the researcher's judgment

Keywords: monitoring telemetry wearable device arrhythmia alarm signal loss satisfaction survey
elucidating the minimal effective dose of prunes for bone health in postmenopausal women

Conditions: Bone Disease, Metabolic

Summary: the objective of this study is to examine if calcium and vitamin d supplements and/or prune can prevent bone loss in postmenopausal women.

two hundred randomly assigned to one of two treatment groups: 1) 30 g prunes and 2) control (0 g prunes). both groups received 500 mg calcium and 400 iu vitamin d as a daily supplement. blood samples are collected at baseline, 12 and 24 months to assess biomarkers of bone turnover. physical activity recall and food records are obtained at baseline, 12 and 24 months to examine physical activity and dietary confounders as potential covariates. dual-energy x-ray absorptiometry (dxa) and peripheral quantitative computed tomography (pqct) will be completed at baseline, 12 and 24 months to examine bone mineral density and structure.

Eligibility criteria:
inclusion criteria: * postmenopausal * bmd t-score is between 0.5 and 2 sd below the mean * not on hormone replacement therapy (hrt) and/or other pharmacological agents known to affect bone for at least three months prior to initiation of the study exclusion criteria: * women whose bmd t-score at any site falls below 2.5 sd of the mean * subjects receiving endocrine (e.g., prednisone, other glucocorticoids) or neuroactive (e.g., dilantin, phenobarbital) drugs or any drugs known to influence bone and calcium metabolism * subjects who smoke cigarettes or vape * regular consumption of dried plum or prune juice

Keywords: osteopenia prune functional food
standard medical management in secondary prevention of ischemic stroke in china

Conditions: Stroke

Summary: the purposes of the study are to analyse the cross-section data of secondary stroke prevention in china and to carry out a standard medical management including medicine and interactive education program,and to evaluate the efficacy and safety of the standard medical management in secondary stroke prevention.


Eligibility criteria:
inclusion criteria: 1. ischemic cerebral infarction or tia within 30 days. 2. aged above 18 years old. 3. hospitalized. 4. cranial ct or mri scan exclude intracranial hemorrhagic diseases 5. stable clinical and neurological conditions. 6. a modified rankin score less than 4 at enrollment 7. informed consent is obtained. exclusion criteria: patients will be excluded from entry if any of the criteria listed below are met 1. documented stroke caused by conditions other than atherosclerosis, ie, surgical or vascular intervention procedure. 2. severe co-morbid or unstable medical condition, ie, heart failure, respiratory failure and renal failure, severe liver dysfunction, malignancy with likelihood of death within the next 2 years 3. significant memory or behavioural disorder, ie, alzheimer disease, etc, daily care needed. 4. a modified rankin score is more than 4 5. concurrent participation in another clinical trial 6. pregnant 7. unable to give informed consent.

Keywords: stroke prevention therapy
establishment of fibroid tissue bank

Conditions: Leiomyoma; Fibroids

Summary: the purpose of this study is to collect information and tissue samples from women with uterine fibroids. the samples will be used to study genes, proteins and other substances in order to better understand the disease process and improve fertility and reproductive health. women who are scheduled to undergo hysterectomy, myomectomy or other surgery due to uterine fibroids or to an unusual variant of fibroid disease, such as hlrcc or benign metastasizing leiomyomatosis, may be eligible for this study. tissue samples are collected from participants during surgery. the samples are coded and catalogued for research use. data collected regarding the surgery include the sample location, surgery type, reason for surgery and the primary and secondary diagnoses. additional data collected about the participant include date of birth, race, ethnicity, weight, height, smoking status, information about menstrual cycles, medications and family history.

the long term goal of this protocol is to create a repository of well-characterized fibroid (leiomyoma) tissues in order to gather information that will lead to improved understanding of uterine fibroid growth and pathogenesis. it is expected that this initiative will eventually improve fertility and reproductive health of the millions of women who suffer from fibroids. to address the need for increased research in this field, the nichd in collaboration with the office of research on women s health (orwh) will establish a national fibroid tissue bank. this initiative will strengthen the science base, improve our understanding of how uterine fibroids develop and grow, and provide clues to more effective conservative management of fibroids. the rationale for this protocol is that a repository of well-characterized, well-preserved leiomyoma tissues will provide investigators interested in basic and translational research on fibroids the opportunity to study the condition. this will facilitate research because experiments conducted on the samples may be expected to improve understanding of the mechanism and pathophysiology of this disease.

Eligibility criteria:
* inclusion criteria: * women aged 21-80 with uterine fibroids * medically indicated hysterectomy, myomectomy or other surgery for uterine fibroids. * samples from patients with unusual variants of fibroid disease (hlrcc, benign metastasizing leiomyomatosis) will be included. these samples may possibly not arise from the uterus proper, as the leiomyoma may have become located elsewhere in the body. exclusion criteria: * inability to give consent or understand the consent forms. * hiv-infected tissues will be excluded due to concern of equipment contamination. * hepatitis-infected tissues will be excluded due to concern of equipment contamination.

Keywords: leiomyoma uterus fibroids surgical
cyc065 cdk inhibitor and venetoclax study in relapsed/refractory aml or mds

Conditions: AML; MDS

Summary: a phase i combination study of cyc065 and venetoclax for relapsed or refractory aml or mds

this is an open-label, single arm, dose escalation study in patients with relapsed or refractory aml or mds. treatment will be administered on an outpatient basis and all patients will receive cyc065 over 4-hour infusion once every 2 weeks on day 1 and day 15 in combination with venetoclax. one treatment cycle is 4 weeks.

Eligibility criteria:
inclusion criteria: * previously treated aml or mds based on who classification and having at least 10% blasts in peripheral blood * ecog 0-2 * adequate renal function * adequate liver function * inr \<=1.2 in patients not receiving chronic anticoagulation * at least 2 weeks from prior cytotoxic chemotherapy, radiation therapy, major surgery or other investigational cancer therapy * agree to practice effective contraception exclusion criteria: * aml is of the subtype of apl or extramedullary myeloid tumor without bone marrow involvment * known aml involvement in cns that is symptomatic and active * currently receiving radiotherapy, biological therapy, or any other investigational agents * uncontrolled intercurrent illness * pregnant or lactating * known to be hiv-positive * known active hepatitis b and/or hepatitis c infection

Keywords: cyc065 cdk2/9 venetoclax bcl-2 mcl-1 relapsed refractory acute myeloid leukemia myelodysplastic syndromes aml mds
comparison of aflibercept versus ranibizumab in management of diabetic macular edema (dme)

Conditions: Diabetic Macular Edema

Summary: diabetic macular edema (dme) is a sign of diabetic retinopathy that affects central vision. it is also a leading cause of visual decline in younger patients, especially in developing countries like our arab community. intra-vitrreal injection of anti-vascular endothelial growth factor (avegf) in management of dme had significant improvement in the final logmar un-corrected distant visual acuity ( ucdva) and logmar best corrected distant visual acuity (bcdva), as well as reduction in the central retinal thickness from baseline measurement.

the investigators randomly assigned four hundreds eyes of diabetic patients with central diabetic macular edema for intra-vitreal injection of avegf group i (200 patients eyes) received aflibercept 2.0 mg and group ii (200 patients eyes) received ranibizumab 0.3 mg. injection was at 4 weeks interval according to the used protocol. the primary outcome was measuring the mean change in visual acuity as functional outcome and the secondary outcomes were the mean change in central macular thickness, as anatomical outcome rather than safety and efficacy of those two anti-vegf drugs.

Eligibility criteria:
inclusion criteria: * patients with type 1 or 2 diabetes mellitus with central dme clinically as well as documented by optical coherence tomography (oct) imaging * the age of the patients at least 20 years old * patients not receiving avegf injection, at least for one year * the bcdva letter score of at least one eye (range, 0 to 115, with higher scores indicating better visual acuity of 90 (snellen = 20/32) to 40 (snellen = 20/320) and central dme . exclusion criteria: * patients with cataract * glaucoma patient * previous avegf injection in less than one year * patients not attending all of the scheduled follow up visits